We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $21.9M | Put options by funds: $12.3M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 31

2% more funds holding

Funds holding: 228232 (+4)

9% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 85

19% less capital invested

Capital invested by funds: $5.13B → $4.15B (-$971M)

Holders
232
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
5.17%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
36
Increased
77
Reduced
85
Closed
31
Calls
$21.9M
Puts
$12.3M
Net Calls
+$9.55M
Net Calls Change
-$5.66M
Name Holding Trade Value Shares
Change
Change in
Stake
GI
151
GAMCO Investors
Connecticut
$588K +$60.7K +400 +11%
Susquehanna International Group
152
Susquehanna International Group
Pennsylvania
$588K +$638K +4,201 New
TC
153
Telemus Capital
Michigan
$586K -$123K -813 -16%
PA
154
Pinnacle Associates
New York
$561K -$48.6K -320 -7%
WG
155
Winton Group
United Kingdom
$553K -$100K -659 -14%
BI
156
BVF Inc
California
$552K -$22K -145 -4%
AB
157
Amalgamated Bank
New York
$550K +$357K +2,353 +149%
AAM
158
Advisors Asset Management
Colorado
$531K +$291K +1,915 +102%
Envestnet Asset Management
159
Envestnet Asset Management
Illinois
$521K +$565K +3,720 New
Allianz Asset Management
160
Allianz Asset Management
Germany
$501K -$283K -1,865 -34%
AIA
161
Affinity Investment Advisors
California
$499K -$52.1K -343 -9%
JRP
162
Jasper Ridge Partners
California
$484K
William Blair & Company
163
William Blair & Company
Illinois
$461K +$117K +771 +31%
SGAM
164
Smith Group Asset Management
Texas
$440K -$15.2K -100 -3%
BC
165
Brinker Capital
Pennsylvania
$418K +$453K +2,986 New
SCM
166
Silvant Capital Management
Georgia
$417K
Nomura Asset Management
167
Nomura Asset Management
Japan
$415K
ADEF
168
Adams Diversified Equity Fund
Maryland
$406K -$15.2K -100 -3%
Prudential Financial
169
Prudential Financial
New Jersey
$395K -$453K -2,985 -51%
Cambridge Investment Research Advisors
170
Cambridge Investment Research Advisors
Iowa
$375K -$15.2K -100 -4%
Neuberger Berman Group
171
Neuberger Berman Group
New York
$350K -$759K -5,000 -67%
Canada Life
172
Canada Life
Manitoba, Canada
$347K
SAM
173
Shell Asset Management
Netherlands
$340K -$30.4K -200 -8%
HSBC Holdings
174
HSBC Holdings
United Kingdom
$338K +$104K +682 +40%
OAM
175
Oppenheimer Asset Management
New York
$312K +$338K +2,224 New

LOXO Hedge Fund Activity: Q4 2018 in Review

232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.

  • 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
  • Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
  • The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.

Based on aggregated 13F filings for Q4 2018.